Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBNNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.356NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.462NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.147NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.6 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.5 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.4 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.420NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.39.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.233NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.320NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.635NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.19 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
N.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AM.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.15 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.113NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.411NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.417NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.319NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.182NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.430NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.331NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.112.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
N.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.515NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.287NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.431NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.170NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.506NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.6.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used